2026 Q2 Portfolio Activity
In 2026 Q2, Octagon Capital Advisors LP maintained a portfolio of 34 distinct positions. The most significant new addition was SUMMIT THERAPEUTICS INC, now representing 1.64% of the total fund value. They heavily accumulated shares in DEFINIUM THERAPEUTICS INC, increasing the position by 20.9%. Conversely, Octagon Capital Advisors LP completely exited their position in CENTESSA PHARMACEUTICALS PLC.
Position History
hover any row below to update
Loading…
Total Positions
34
Quarter
2026 Q2
Top Holding
DNTH (16.1%)
Top 10 Concentration
78.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-34 of 34
Octagon Capital Advisors LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 16.14% | 18.08% |
#1
Prev: #1
|
6.5 |
—
|
-105,000 | -5.4% |
P
S
|
1,841,667 | $179,525,699 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 12.47% | 5.10% |
#2
3
Prev: #5
|
8.0 |
—
|
510,000 | 20.9% |
P
S
|
2,950,000 | $138,768,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 11.89% | 8.34% |
#3
Prev: #3
|
7.5 |
—
|
316,000 | 46.7% |
P
S
|
993,000 | $132,327,180 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 8.17% | 10.01% |
#4
2
Prev: #2
|
4.8 |
—
|
no change | no change |
P
S
|
2,350,000 | $90,945,000 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALMS
ALUMIS INC
|
Healthcare | 7.16% | 6.90% |
#5
1
Prev: #4
|
4.4 |
—
|
no change | no change |
P
S
|
2,830,700 | $79,655,898 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AVBP
ARRIVENT BIOPHA...
|
Healthcare | 6.15% | 5.03% |
#6
Prev: #6
|
3.5 |
—
|
no change | no change |
P
S
|
1,971,054 | $68,474,416 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 5.93% | 4.38% |
#7
Prev: #7
|
4.4 |
—
|
833,333 | 9.4% |
P
S
|
9,693,244 | $66,010,992 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BIOA
BIOAGE LABS INC
|
Healthcare | 3.85% | 3.38% |
#8
2
Prev: #10
|
2.5 |
—
|
no change | no change |
P
S
|
1,748,000 | $42,843,480 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 3.57% | 3.46% |
#9
Prev: #9
|
2.4 |
—
|
no change | no change |
P
S
|
338,900 | $39,675,023 | 2022 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 3.20% | 3.92% |
#10
2
Prev: #8
|
1.3 |
—
|
-115,000 | -27.1% |
P
S
|
310,000 | $35,547,700 | 2021 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
AKTIS ONCOLOGY ...
|
|
Unknown | 2.78% | 1.90% |
#11
8
Prev: #19
|
2.1 |
—
|
no change | no change |
P
S
|
960,847 | $30,968,099 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
XENE
XENON PHARMACEU...
|
Healthcare | 2.66% | 3.15% |
#12
1
Prev: #13
|
2.1 |
—
|
no change | no change |
P
S
|
490,000 | $29,576,400 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
CALL
ERASCA INC
|
|
CALL Option | 2.07% | — |
#13
Prev: #—
|
4.3 |
—
|
1,255,000 | — |
NEW
|
1,255,000 | $22,991,600 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
PALI
PALISADE BIO IN...
|
Healthcare | 1.93% | 1.99% |
#14
2
Prev: #16
|
1.8 |
—
|
no change | no change |
P
S
|
10,276,317 | $21,477,503 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 1.83% | 2.97% |
#15
Prev: #15
|
0.7 |
—
|
-1,091,600 | -34.5% |
P
S
|
2,075,000 | $20,376,500 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 1.78% | 1.91% |
#16
2
Prev: #18
|
1.7 |
—
|
no change | no change |
P
S
|
270,000 | $19,747,800 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SMMT
SUMMIT THERAPEU...
|
Healthcare | 1.64% | — |
#17
Prev: #—
|
4.2 |
—
|
1,250,000 | — |
NEW
|
1,250,000 | $18,212,500 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 1.42% | 0.52% |
#18
8
Prev: #26
|
3.6 |
—
|
291,721 | 176.8% |
P
S
|
456,721 | $15,793,412 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ANL
ADLAI NORTYE LT...
|
Healthcare | 0.97% | — |
#19
Prev: #—
|
3.9 |
—
|
934,716 | — |
NEW
|
934,716 | $10,749,234 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DTIL
PRECISION BIOSC...
|
Healthcare | 0.95% | 1.36% |
#20
1
Prev: #21
|
0.4 |
—
|
-886,732 | -39.6% |
P
S
|
1,350,000 | $10,611,000 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DBVT
DBV TECHNOLOGIE...
|
Healthcare | 0.85% | 1.33% |
#21
1
Prev: #22
|
1.3 |
—
|
no change | no change |
P
S
|
574,200 | $9,416,880 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SNSE
FAETH THERAPEUT...
|
Healthcare | 0.81% | — |
#22
Prev: #—
|
3.8 |
—
|
361,010 | — |
NEW
|
361,010 | $9,025,250 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GYRE
GYRE THERAPEUTI...
|
Healthcare | 0.57% | — |
#23
Prev: #—
|
3.7 |
—
|
954,416 | — |
NEW
|
954,416 | $6,289,601 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 0.53% | 1.96% |
#24
7
Prev: #17
|
0.2 |
—
|
-1,170,000 | -78.8% |
P
S
|
315,000 | $5,874,750 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
UNCY
UNICYCIVE THERA...
|
Healthcare | 0.42% | 0.73% |
#25
2
Prev: #23
|
1.2 |
—
|
no change | no change |
P
S
|
1,000,000 | $4,690,000 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CNTX
CONTEXT THERAPE...
|
Healthcare | 0.15% | 1.52% |
#26
6
Prev: #20
|
0.1 |
—
|
-2,200,000 | -41.9% |
P
S
|
3,050,000 | $1,689,395 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GOSS
GOSSAMER BIO IN...
|
Healthcare | 0.11% | 0.28% |
#27
2
Prev: #29
|
1.0 |
—
|
no change | no change |
P
S
|
7,750,000 | $1,275,650 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
EVMN
EVOMMUNE INC
|
Healthcare | 0.00% | 0.37% |
Sold All 😨
(Was: #28) |
0.0 |
—
|
-143,472 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CATX
PERSPECTIVE THE...
|
Healthcare | 0.00% | 0.37% |
Sold All 😨
(Was: #27) |
0.0 |
—
|
-791,555 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 0.00% | 0.70% |
Sold All 😨
(Was: #25) |
0.0 |
—
|
-1,100,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 0.00% | 0.71% |
Sold All 😨
(Was: #24) |
0.0 |
—
|
-719,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 0.00% | 3.09% |
Sold All 😨
(Was: #14) |
0.0 |
—
|
-530,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KALV
KALVISTA PHARMA...
|
Healthcare | 0.00% | 3.23% |
Sold All 😨
(Was: #12) |
0.0 |
—
|
-1,450,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 0.00% | 3.30% |
Sold All 😨
(Was: #11) |
0.0 |
—
|
-750,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-34 of 34 holdings